Skip to main content
Home
Latest news
Browse topics
Lupus
Rheumatoid arthritis
Spondyloarthropathies
COVID-19
Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA
Anifrolumab for the treatment of SLE
JAK inhibitor safety: Weighing up the data and understanding the risks
Rituximab and rheumatology practice in the COVID-19 era
Safety snapshot: Upadacitinib in patients with PsA
Repurposing rheumatology drugs for COVID-19
Telemedicine in rheumatology: COVID-19 and beyond
Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022
EULAR 2022 Congress
About us

Medicine Matters Rheumatology

Medicine Matters Rheumatology
EXTENDED SEARCH
Log in

Be confident that your patient care is up to date

Register now and start receiving our tailored medical education content from April. You can also secure your place for the first live webinar.

RHEUMATOLOGY NEWS HEADLINES

View all latest news

IN FOCUS | JAK inhibitors

18-10-2022 | Psoriatic arthritis | News

Support for JAK inhibitors as ‘drug of choice’ for patients with PsA and significant joint disease

JAK inhibitors show promise for the treatment of moderate-to-severe psoriasis and psoriatic arthritis, finds a systematic review and meta-analysis of more than 6000 patients.

NEWS | JAK inhibitors

JAK inhibitor safety

Data summary, expert discussion, & research news on the potential risks associated with JAK inhibitors.

IN FOCUS | COVID-19 & rheumatic disease

24-10-2022 | COVID-19 | News

Prophylactic antivirals may help prevent symptomatic COVID-19 in rituximab-treated patients

Pre-exposure prophylaxis with tixagevimab and cilgavimab may be an effective strategy to prevent symptomatic SARS-CoV-2 infection among people with rheumatic diseases treated with rituximab, suggest findings from a real-world study.

More on COVID-19 & rheumatic disease

NEWS | COVID-19 & rheumatic disease

Rituximab and rheumatology practice in the COVID-19 era

How can rheumatologists respond to the challenges associated with rituximab use during the pandemic?

IN FOCUS | Inflammatory arthritis

07-12-2022 | Rheumatoid arthritis | News

Similar reduction in CV risk with different add-on RA treatments

Among patients with active rheumatoid arthritis, adding tumor necrosis factor inhibitors to methotrexate is associated with a similar reduction in vascular inflammation to that seen with add-on sulfasalazine plus hydroxychloroquine, suggest findings from a randomized controlled trial.

NEWS | Inflammatory arthritis

Common scores used in rheumatology

An at-a-glance reference guide to the scores that are commonly used in clinical trials & daily rheumatology practice

IN FOCUS | Gout and crystal arthropathies

04-08-2022 | Gout | News

Gout flares linked to temporary increase in cardiovascular risk

Gout flares are associated with an increased risk for cardiovascular events in the following 120 days, study findings suggest.

NEWS | Gout and crystal arthropathies

Febuxostat and cardiovascular risk in people with gout

How will the FAST trial results impact regulatory guidance & clinical practice?

IN FOCUS | Lupus

14-11-2022 | ACR 2022 | Conference coverage | News

Phase 3 trial supports add-on telitacicept for SLE

Addition of the recombinant fusion protein telitacicept to standard care may reduce disease activity and is well tolerated in people with systemic lupus erythematosus, research suggests.

NEWS | Lupus

Anifrolumab for the treatment of lupus

Perspective on the approval of anifrolumab and the importance of endpoints in lupus trials.

Stay informed with Medicine Matters

Get the latest developments in rheumatology delivered straight to your inbox

Sign up for the e-alert today
Image Credits